Cerebrovascular Accident: Clinical Trials

36 trials for Cerebrovascular Accident, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

26 completed, 6 terminated, 3 unknown, 1 withdrawn. 36 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 336Completed 26, Terminated 6, Unknown 3, Withdrawn 1
Phase 22Terminated 2

Follow Cerebrovascular Accident: new trials by email Literature Review of Cerebrovascular Accident trials Research Report on Cerebrovascular Accident

Trials (filtered) newest first · largest first

All 36 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity
Phase 2; Low Dose MYOBLOC (10,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo - Spasticity, Cerebrovascular Accident
Phase 2 / Phase 3TerminatedSolstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC322021-11-022026-05-27
Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)
Best Practice, Tocilizumab - Cerebrovascular Accident, Chronic Obstructive Pulmonary Disease
Phase 3WithdrawnEmory University2020-04-072020-06-18
Botulinim Toxin Type A Injections by Different Guidance in Stroke Patients With Spasticity on Lower Extremities
Botulinum toxin type A - Cerebrovascular Accident
Phase 3UnknownChang Gung Memorial Hospital402015-10-012015-10-14
A Study to Evaluate the Botulinum Toxin Type A for Injection(HengLi®) in Subjects With Post-stroke Upper Limb Spasticity
Botulinum Toxin Type A for Injection, placebo - Cerebrovascular Accident
Phase 3CompletedLanzhou Institute of Biological Products Co., Ltd1802014-07-012016-09-26
Effectiveness Study on a Virtual Reality Based Training System for Stroke Patients
YouGrabber training device from YouRehab Ltd., Therapy (PT, OT) - Cerebrovascular Accident, Hemorrhagic Stroke
Phase 3CompletedReha Rheinfelden542013-01-012016-04-07
Botulinim Toxin Type A Injections by Different Guidance in Stroke Patients With Spasticity on Upper Extremities
Botulinum Toxin Type A - Cerebrovascular Accident
Phase 3UnknownChang Gung Memorial Hospital402012-09-012016-03-30
Botulinum Toxin Injections by Ultrasounds Guidance and Stretching Exercise in Spastic Toe Clawing
Botulinum Toxin Type A, Stretching exercise - Cerebrovascular Accident
Phase 3CompletedChang Gung Memorial Hospital302010-08-012015-10-26
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Upper Limb Spasticity
GSK1358820(Botulinum toxin type A), placebo - Cerebrovascular Accident
Phase 3CompletedGlaxoSmithKline1702010-04-012017-06-28
The Effect of an Aerobic Exercise Programme in Stroke Patients
Aerobic exercise group, Control group, Follow-up first aerobic exercise group - Cerebrovascular Accident
Phase 3UnknownUniversity College of Antwerp502010-02-012010-04-14
Norwegian Constraint-Induced (CI) Therapy Multisite Trial
Modified CI therapy - Cerebrovascular Accident
Phase 3TerminatedUniversity Hospital of North Norway472008-10-012013-10-10
Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183)
Vorapaxar 2.5 mg, Placebo - Atherosclerosis, Ischemia
Phase 3CompletedMerck Sharp & Dohme LLC2582008-07-012018-09-21
Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)
Telcagepant, Acetaminophen/Paracetamol, Placebo to Telcagepant - Migraine Disorders, Heart Disease
Phase 3CompletedMerck Sharp & Dohme LLC1652008-03-172018-10-19
Melodic-Intonation-Therapy and Speech-Repetition-Therapy for Patients With Non-fluent Aphasia
Melodic Intonation Therapy, Speech-Repetition-Therapy - Aphasia, Stroke
Phase 3CompletedBeth Israel Deaconess Medical Center302008-02-012020-09-21
Intra-arterial Versus Systemic Thrombolysis for Acute Ischemic Stroke
Alteplase IA and/or mechanical thrombolysis, Alteplase IV - Stroke, Cerebrovascular Accident
Phase 3CompletedNiguarda Hospital3502008-02-012014-04-25
Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)
Vorapaxar, Placebo - Atherosclerosis, Ischemia
Phase 3CompletedMerck Sharp & Dohme LLC264492007-09-012018-09-21
Study Of GSK1358820 In Patients With Post-Stroke Upper Limb Spasticity
GSK1358820, Placebo - Post-Stroke Spasticity, Cerebrovascular Accident
Phase 3CompletedGlaxoSmithKline1092007-05-012017-05-30
Study of GSK1358820 In Patients With Post-Stroke Lower Limb Spasticity
GSK1358820, Placebo - Post-Stroke Spasticity, Cerebrovascular Accident
Phase 3CompletedGlaxoSmithKline1202007-05-012010-09-08
Stroke With Transfusions Changing to Hydroxyurea
Red Cell Transfusions, Iron Chelation, Hydroxyurea - Hemochromatosis, Cerebrovascular Accident
Phase 3TerminatedSt. Jude Children's Research Hospital1342006-10-012013-01-18
JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme
Aggrenox capsule, Acetylsalicylic Acid (ASA) - Cerebrovascular Accident
Phase 3CompletedBoehringer Ingelheim12952006-04-012014-02-14
Niacin Plus Statin to Prevent Vascular Events
Extended release niacin, Simvastatin - Cardiovascular Diseases, Heart Diseases
Phase 3TerminatedAxio Research. LLC34142005-09-012016-04-06

Showing 20 of 36. Sign in to see all of them.

Narrower conditions

Stroke (36)  ·  Muscle Spasticity (8)  ·  Heart Diseases (5)  ·  Cardiovascular Diseases (4)  ·  Ischemic Stroke (4)  ·  Myocardial Infarction (4)  ·  Atherosclerosis (3)  ·  Hematologic Diseases (3)  ·  Ischemia (3)  ·  Anemia, Sickle Cell (2)  ·  Arrhythmias, Cardiac (2)  ·  Atrial Fibrillation (2)  ·  Brain Ischemia (2)  ·  Cerebrovascular Disorders (2)  ·  Vascular Diseases (2)

Broader conditions

Brain Diseases (36)  ·  Central Nervous System Diseases (36)  ·  Nervous System Diseases (36)  ·  Cerebrovascular Disorders (34)  ·  Vascular Diseases (34)  ·  Cardiovascular Diseases (32)  ·  Pathological Conditions, Signs and Symptoms (20)  ·  Pathologic Processes (12)  ·  Neurologic Manifestations (9)  ·  Signs and Symptoms (9)  ·  Muscle Hypertonia (8)  ·  Muscular Diseases (8)  ·  Musculoskeletal Diseases (8)  ·  Neuromuscular Manifestations (8)  ·  Infarction (6)

Interventions

Botulinum Toxins, Type A (5)  ·  Botulinum Toxins (3)  ·  Aspirin (2)  ·  Constraint Induced Movement Therapy (2)  ·  vorapaxar (2)  ·  Abciximab (1)  ·  Acetaminophen (1)  ·  Amiodarone (1)  ·  Aspirin, Dipyridamole Drug Combination (1)  ·  Blood Transfusion (1)  ·  Clinical Trials, Phase II as Topic (1)  ·  Clinical Trials, Phase III as Topic (1)  ·  Clopidogrel (1)  ·  Control Groups (1)  ·  Disulfides (1)

Sponsors

Boehringer Ingelheim (3)  ·  Chang Gung Memorial Hospital (3)  ·  GlaxoSmithKline (3)  ·  Merck Sharp & Dohme LLC (3)  ·  Niguarda Hospital (2)  ·  Axio Research. LLC (1)  ·  Beth Israel Deaconess Medical Center (1)  ·  Centocor, Inc. (1)  ·  CoAxia (1)  ·  Emory University (1)  ·  Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1)  ·  Jeffrey L. Saver (1)  ·  Lanzhou Institute of Biological Products Co., Ltd (1)  ·  Massachusetts General Hospital (1)  ·  Mt. Sinai Medical Center, Miami (1)

Countries

United States (12)  ·  Canada (5)  ·  Taiwan (5)  ·  Belgium (3)  ·  Hungary (3)  ·  Italy (3)  ·  Japan (3)  ·  Spain (3)  ·  Switzerland (3)  ·  Austria (2)  ·  Germany (2)  ·  Norway (2)  ·  Poland (2)  ·  Chile (1)  ·  China (1)

Top investigators

Pong Ya-Ping, MD (3)  ·  Alfonso Ciccone, MD (2)  ·  Ajay K Nooka (1)  ·  Andrea Norton, BM (1)  ·  Ashfaq Shuaib, MD (1)  ·  Audny GM Anke, MD, PhD (1)  ·  Bent Indredavik, MD, PhD (1)  ·  Bramah N. Singh (1)  ·  Bryan Due, Ph.D. (1)  ·  Daniel Kiper, PD PhD (1)  ·  Dirk Vissers, dr. (1)

Results publications

PMID 35224730, PMID 12914883, PMID 16382063, PMID 17077374, PMID 18032739, PMID 18077218, PMID 18815396, PMID 19673813, PMID 19699854, PMID 19721013, PMID 19850525, PMID 20358216, PMID 20446946, PMID 20569068, PMID 20814005, PMID 21197418, PMID 21371282, PMID 21372306, PMID 21502757, PMID 21566232, PMID 21826782, PMID 21899409, PMID 21990564, PMID 22085343, PMID 22168590, PMID 22221076, PMID 22318199, PMID 22443427, PMID 22499292, PMID 22750086, PMID 22826359, PMID 22931315, PMID 22932716, PMID 23034910, PMID 23291425, PMID 23387822, PMID 23396280, PMID 23501976, PMID 23549132, PMID 23726159, PMID 23736109, PMID 23828106, PMID 23861242, PMID 23881958, PMID 23916935, PMID 23973688, PMID 24177006, PMID 24523037, PMID 24661819, PMID 24862645

NIH funding

P30CA138292 (1), R01DC008796 (1), R01HL033233 (1), U01HL049804 (1), U01HL052016 (1), U01HL073958 (1), U01HL074815 (1), U01HL078787 (1), U01HL081616 (1), U01HL081649 (1), U01NS044364 (1)